Filtered By:
Condition: Heart Failure
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 376 results found since Jan 2013.

'Dying of heartache?' Heart problems linked to bereavement
Conclusion The study found that people were more likely to have AF for the first time in the weeks immediately after a bereavement, but that this raised risk does not last. Despite the headlines, this does not mean that anyone who's had a bereavement is at immediate risk of "dying of a broken heart". Atrial fibrillation is treatable and not usually life-threatening. Because this was an observational study, we cannot rule out the possibility that factors such as family history of atrial fibrillation or lifestyle factors could have affected the results, although the researcher's conclusion that this is a small poss...
Source: NHS News Feed - April 6, 2016 Category: Consumer Health News Tags: Heart/lungs Mental health Source Type: news

Preeclampsia and the Risk of Future Vascular Disease and Mortality: A Review
DiscussionPreeclampsia is associated with an increased risk for future chronic hypertension, CVD, cerebrovascular disease, and death. While evidence shows that women with cardiac risk factors may have a higher chance of developing preeclampsia, many women with preeclampsia have no CVD risk factors. Measures to prevent preeclampsia such as calcium supplementation for women with low calcium intake and low‐dose aspirin for women with a history of more than one incident of preeclampsia or a preterm birth associated with preeclampsia are supported by evidence. Reduction of modifiable risks associated with CVD before, during, ...
Source: Journal of Midwifery and Women's Health - February 29, 2016 Category: Midwifery Authors: Mayri Sagady Leslie, Linda A. Briggs Tags: Review Source Type: research

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
CONCLUSIONS: There is evidence from RCTs to suggest that neither oral anticoagulation with warfarin or platelet inhibition with aspirin is better for mortality in systolic heart failure with sinus rhythm (high quality of the evidence for all-cause mortality and moderate quality of the evidence for non-fatal cardiovascular events and major bleeding events). Treatment with warfarin was associated with a 20% reduction in non-fatal cardiovascular events but a twofold higher risk of major bleeding complications (high quality of the evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (lo...
Source: Cochrane Database of Systematic Reviews - September 14, 2016 Category: Journals (General) Authors: Shantsila E, Lip GY Tags: Cochrane Database Syst Rev Source Type: research

Clinical outcomes associated with per ‐operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta‐analysis
Conclusion: Our analysis suggests that planned short‐term discontinuation in the appropriate clinical setting appears to be safe in the correct clinical setting with no increased risk of thrombotic events and with a decreased risk of bleeding. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - September 23, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Faraz Khan Luni, Haris Riaz, Abdur Rahman Khan, Talha Riaz, Muhammad Husnain, Irbaz Bin Riaz, Muhammad Shahzeb Khan, Mohammed Taleb, Yusuf Kanjwal, Christopher J. Cooper, Sadik A. Khuder Tags: Coronary Artery Disease Source Type: research

Beta-blockers 'useless' for many heart attack patients, study reports
Conclusion This study aimed to see whether beta blockers reduce mortality in people who've had a heart attack but who don't have heart failure or systolic dysfunction. It found no difference between those who were and those who were not given beta-blockers on discharge from hospital. The authors say this adds to the evidence that routine prescription of beta blockers might not be needed for patients without heart failure following a heart attack. Current UK guidelines recommend all people who have had a heart attack take beta blockers for at least one year to reduce risk of recurrent events. Only people with heart failure ...
Source: NHS News Feed - May 30, 2017 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Risk factors for the primary effectiveness endpoint in secondary prevention of acute coronary syndrome with antiplatelet agents: A cohort in the nationwide French claims and hospitalisation database
Conclusions In this nationwide real-life study, the risk factor most associated with the primary effectiveness endpoint was a Charlson comorbidity index>5.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40  months clinical outcome after primary PCI
Conclusion Clopidogrel dose-adjusted plasma concentration in STEMI patients, as well as multivessel coronary artery disease, showed significance in predicting an unfavorable composite clinical outcome after 40-month follow-up.
Source: International Journal of Clinical Pharmacy - October 26, 2018 Category: Drugs & Pharmacology Source Type: research

79-Year-Old Man With Shortness of Breath and Fevers
A 79-year old man with a history of myocardial infarction and coronary artery bypass grafting in 2000, biventricular systolic heart failure with an ejection fraction of 27%, hypertension, persistent atrial fibrillation for which he was taking high-dose aspirin given a previous history of hemorrhagic stroke, stage 3 chronic kidney disease, left cerebellar ischemic stroke, and implantable cardioverter-defibrillator (ICD) placement 5 years previously presented to his local medical facility with a 2-day history of breathlessness, fevers, and chills.
Source: Mayo Clinic Proceedings - November 7, 2018 Category: Internal Medicine Authors: Jaskanwal D. Sara, Megha Prasad, Suraj Kapa Tags: Residents' clinic Source Type: research

The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction 
.
CONCLUSION: In patients with acute MI treated with PCI, lower dose-adjusted clopidogrel and dose-adjusted 2-oxo-clopidogrel plasma concentrations were associated with an increased risk of ischemic events.
. PMID: 30431425 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - November 17, 2018 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Determinants of Antithrombotic Treatment for Atrial Fibrillation in Octogenarians: Results of the OCTOFA Study
ConclusionsMost private-practice cardiologists prescribe anticoagulant treatment according to current guidelines in elderly atrial fibrillation patients. Non-vitamin K antagonist oral anticoagulants represent a significant proportion of prescriptions.
Source: Clinical Drug Investigation - June 9, 2019 Category: Drugs & Pharmacology Source Type: research

Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea
ConclusionAspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia. Moreover, the benefits of the long-term use of aspirin in reducing the risks of MACCE were demonstrated. However, the decision of using aspirin for primary prevention must be carefully made on an individual basis, while estimating the benefit –risk balance of aspirin.
Source: Drugs and Aging - November 21, 2019 Category: Geriatrics Source Type: research

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial.
CONCLUSIONS: As an add-on to OMT, MUSKARDIA is safe and significantly reduces angina frequency in patients with stable CAD. Moreover, the use of MUSKARDIA is associated with a trend toward reduced MACEs in patients with stable CAD. The results suggest that MUSKARDIA can be used to manage patients with CAD. TRIAL REGISTRATION: No. ChiCTR-TRC-12003513. PMID: 33273369 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - December 2, 2020 Category: General Medicine Authors: Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, Zhao YL, Qian J, Jin YZ, Liu YW, Wang SH, He SH, Yang P, Wu J, Lu F, Hou ZS Tags: Chin Med J (Engl) Source Type: research

Aspirin and Left Ventricular Assist Devices Rationale and Design for The International Randomized, Placebo ‐Controlled, Non‐Inferiority ARIES HM3 Trial
ConclusionThis paper reviews the biological and clinical role of aspirin (100  mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - June 19, 2021 Category: Cardiology Authors: Mandeep R. Mehra, Daniel L. Crandall, Finn Gustafsson, Ulrich P. Jorde, Jason N. Katz, Ivan Netuka, Nir Uriel, Jean M. Connors, Poornima Sood, Gerald Heatley, Francis D. Pagani Tags: Study Design Source Type: research

Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo ‐controlled, non‐inferiority ARIES HM3 trial
ConclusionThis paper reviews the biological and clinical role of aspirin (100  mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.
Source: European Journal of Heart Failure - July 2, 2021 Category: Cardiology Authors: Mandeep R. Mehra, Daniel L. Crandall, Finn Gustafsson, Ulrich P. Jorde, Jason N. Katz, Ivan Netuka, Nir Uriel, Jean M. Connors, Poornima Sood, Gerald Heatley, Francis D. Pagani Tags: Study Design Paper Source Type: research